RecruitingNCT06365034
Study on the Efficacy and Safety of Conversion Therapy in Patients With Initially Unresectable Hepatocellular Carcinoma
A Single-center, Retrospective Study on the Efficacy and Safety of Conversion Therapy for Patients With Initially Unresectable Hepatocellular Carcinoma
Sponsor
Qianfoshan Hospital
Enrollment
92 participants
Start Date
Mar 1, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
To evaluate the efficacy and safety of conversion therapy in patients with initially unresectable hepatocellular carcinoma (uHCC).
Eligibility
Min Age: 18 Years
Inclusion Criteria6
- ≥ 18 years old, gender is not limited;
- Patients with radiographically or pathologically confirmed, unresectable advanced hepatocellular carcinoma;
- At least one measurable lesion according to the mRECIST criteria as the target lesion;
- No prior immunotherapy, including but not limited to anti-CTLA-4, anti-PD-1, and anti-PD-L1 antibodies;
- Patients with an ECOG score of 0-2 were included according to the activity status score scale developed by the Eastern Cooperative Oncology Group (ECOG) in the United States;
- Child-Pugh liver function is graded as A or B.
Exclusion Criteria9
- Have a history of immunodeficiency, or have other acquired or congenital immunodeficiency diseases;
- Have other malignancies;
- Presence of any active autoimmune disease or history of autoimmune disease (including, but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism), or known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation, or other patients who are considered by the investigator to have an impact on study treatment;
- Long-term heavy use of corticosteroids or other immunomodulators;
- Serious illness in combination with other systems;
- Received a live or attenuated vaccine within 30 days prior to the first dose, or plans to receive a live or attenuated vaccine during the study, excluding the new crown vaccine;
- Known human immunodeficiency virus (HIV) infection;
- Have participated in other therapeutic clinical studies;
- Incomplete clinical data.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06365034
Related Trials
A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular Carcinoma
NCT070104971 location
Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma
NCT053668292 locations
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
NCT038949171 location
Hepatocellular Carcinoma on Cirrhosis With Child A/B7 and Hepatic Intra Arterial Injection of Idarubicin/Lipiodol Emulsion
NCT037276334 locations
A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
NCT072270121 location